Seegene, Inc. (096530) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Seegene, Inc. (096530:KRX), powered by AI.
- Current Price
- ₩28,700
- P/E Ratio
- 31.0
- Market Cap
- 1.5T
- Sector
- Healthcare
What is the Seegene, Inc. stock price forecast?
Seegene, Inc. is currently trading at ₩28,700. View real-time AI analysis on Alpha Lenz.
What is Seegene, Inc. insider trading activity?
View the latest insider trading data for Seegene, Inc. on Alpha Lenz.
What is Seegene, Inc.'s P/E ratio?
Seegene, Inc.'s P/E ratio is 31.0.
Seegene, Inc.
KRX · 096530“Seegene, Inc. trades at a P/E of 31.0 (premium valuation) with modest ROE of 4.8%.”
Ask for details →Company Overview
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Seegene, Inc. trades at a P/E of 31.0 (premium valuation) with modest ROE of 4.8%.”
Ask for details →Frequently Asked Questions
Seegene, Inc. (ticker: 096530) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 63 employees. Market cap is $1.5T.
The current price is ₩28,700 with a P/E ratio of 31.05x and P/B of 1.48x.
ROE is 4.84% and operating margin is 7.29%. Annual revenue is $474.2B.